Gel embolism microsphere capable of loading multiple drugs and realizing sustained release
By adopting a multi-layer gel microsphere structure, using macromolecules containing phosphazene structure and modified polyvinyl alcohol, a variety of drug loads and sustained releases that are difficult to achieve in traditional embolizers, solving the drug release in traditional technologies The problem of inequality improves the efficacy and safety of treatment.
Patent Information
- Application Number
- CN202411169712.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-25
- Publication Date
- 2024-11-15
AI Technical Summary
In traditional transarterial chemoembolization technology, it is difficult for embolizing agents to load multiple drugs at the same time and achieve gradual release of drugs, resulting in limited therapeutic effects.
A gel microsphere structure consisting of a multi-layer structure, including an oily drug-loading core, a hydrophilic drug-loading shell and a surface drug-loading layer, using macromolecules containing phosphazene structures, amide-based polymers and modified polyvinyl alcohols, through micro Flow control technology and nano-scale atomization spraying device preparation to achieve loading and sustained release of a variety of drugs.
The continuous sustained release of a variety of drugs has been achieved, which improves the therapeutic effect, enhances the local concentration and efficacy of the drug, while reducing systemic toxicity and prolongs the contact time between the drug and tumor tissue.
Smart Images

Figure CN118949111A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to gel embolic microspheres and a preparation method thereof, and in particular to gel microspheres for vascular embolism which can simultaneously load multiple drugs and realize gradual drug release and a preparation method thereof. Background Art
[0002] Transarterial chemoembolization (TACE) is a method of injecting anti-tumor drugs and embolizing malignant tumors (cancer) is one of the most common causes of death. According to statistics from the World Health Organization's International Agency for Research on Cancer (IARC), there were 19.29 million new cancer cases worldwide in 2020, of which 4.57 million were new cancer cases in China, accounting for 23.7% of the world. The treatment of cancer is still a major global problem, especially for certain specific diseases such as liver cancer. The early symptoms are hidden, and most patients are diagnosed in the middle and late stages. At this time, surgical resection is difficult, and the treatment and prognosis are relatively poor. Patients are in urgent need of safe and effective anti-cancer technology to prolong survival time and improve the quality of life. Transarterial chemoembolization (TACE) is a minimally invasive technology that selectively injects embolic agents or anti-cancer drugs combined with microparticles to embolize the tumor's blood supply artery. It is a type of interventional vascular treatment technology. Its advantages are: on the one hand, it embolizes the blood supply artery of the tumor, causing ischemia, hypoxia and necrosis of the tumor tissue; on the other hand, it increases the local drug concentration and prolongs the contact time between the drug and the tumor tissue, and the efficacy is significantly improved compared with simple perfusion chemotherapy and simple embolization. TACE is suitable for palliative treatment and relatively radical treatment of liver cancer, kidney cancer, pancreatic cancer, lung cancer, pelvic malignancies, etc., and radical treatment of hepatic hemangioma. In 2021, the total number of TACE surgeries in China will reach about 500,000, and the number of surgeries is increasing year by year.
[0003] The therapeutic effect of TACE depends largely on the performance and characteristics of the embolic agent. Traditional embolic agents are iodized oil / chemotherapeutic drug mixed liquid reagents. Due to their fluidity, they are easy to reduce the efficacy of drugs and cause systemic toxicity. In order to improve the shortcomings of traditional methods, many types of solid embolic agents have been developed and applied, such as gelatin sponges, polyvinyl alcohol particles, microspheres, etc. These new embolic agents can be better fixed in blood vessels, have no toxic side effects, and have improved therapeutic effects, but there are also some functional defects. The typical defect is that the microspheres have no pre-loaded medicinal properties, and need to be immersed in drug solutions for a long time before the operation to load drugs. At the same time, generally only one drug can be loaded by immersion, so that the needs of combined drug therapy cannot be met, and drugs often cannot achieve long-term sustained release, which also limits their therapeutic effects. The present invention is to overcome the above defects, and a multi-layered gel microsphere has been developed, each layer is different in characteristics, and different types of drugs can be loaded, so as to achieve the purpose of multiple sustained-release combined drug therapy. Summary of the invention
[0004] The present invention aims to solve at least the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a core-shell structure gel microsphere, which can directly load drugs with different characteristics, and can load drugs outside the shell layer, so as to achieve sustained release of multiple drugs.
[0005] A gel embolic microsphere capable of loading multiple drugs and sustained release comprises an oily drug-loaded core, a hydrophilic drug-loaded shell and a surface drug-loaded layer; wherein the oily drug-loaded core comprises a macromolecule containing a phosphazene structure, an amide-based polymer and an oily drug; the hydrophilic drug-loaded shell is a polyvinyl alcohol-modified polymer and a water-soluble drug solution, and the outer layer of the hydrophilic drug-loaded shell realizes the introduction of a surface drug covering layer by accessing surfactant groups.
[0006] Furthermore, the macromolecule containing the phosphazene structure includes one of poly(bis(2,2,2-trifluoroethoxy)phosphazene), poly(bis(phenoxy)phosphazene), and poly(bis(4-carboxyphenoxy)phosphazene), and the material structure is as follows: Poly(bis(2,2,2-trifluoroethoxy)phosphazene): ;
[0007] Poly(bis(phenoxy)phosphazene): ;
[0008] Poly(bis(4-carboxyphenoxy)phosphazene): .
[0009] Furthermore, the amide polymer is a polymer obtained by polymerizing 3-acrylamide-phenol, N-p-hydroxyphenylacrylamide, and 3-acrylamidephenylboronic acid as monomers; the monomer structural formula is as follows: 3-Acrylamido-phenol: ;
[0010] N-p-Hydroxyphenylacrylamide: ;
[0011] 3-Acrylamidophenylboronic acid: .
[0012] Furthermore, the polyvinyl alcohol-modified polymer of the hydrophilic drug-carrying shell is a cation-modified polyvinyl alcohol or anion-modified polyvinyl alcohol, which can be used to load cationic drugs and anionic drugs; wherein the cation-modified polyvinyl alcohol is a quaternary ammonium cationic polyvinyl alcohol, and the anion-modified polyvinyl alcohol is a sulfonic acid polyvinyl alcohol or a carboxyl polyvinyl alcohol, and the ion concentration is between 0.5-0.8 mol / mol polyvinyl alcohol.
[0013] Furthermore, the quaternary ammonium cationic polyvinyl alcohol is prepared using trimethylamine, epichlorohydrin and polyvinyl alcohol as raw materials, and the molecular formula is as follows:
[0014] Furthermore, the anion-modified polyvinyl alcohol is sulfonic acid-modified polyvinyl alcohol or carboxyl-modified polyvinyl alcohol; typically, sulfonic acid-modified polyvinyl alcohol can be obtained by modifying polyvinyl alcohol with acrylamide formaldehyde and then modifying it with acrylamide-sulfonic acid ion monomers, thereby introducing sulfonate groups on the side chains of polyvinyl alcohol; similarly, carboxyl-modified polyvinyl alcohol can be obtained by modifying polyvinyl alcohol with acrylamide formaldehyde and then modifying it with acrylamide-carboxylic acid ion monomers, thereby introducing carboxyl groups on the side chains of polyvinyl alcohol.
[0015] Furthermore, the molecular weight of the polyvinyl alcohol is between 2000-5000, and the alcoholysis degree is between 70%-95%.
[0016] Furthermore, the preparation process of the microspheres is: (1) dissolving a macromolecule containing a phosphazene structure, an amide monomer, and an oily drug in an oily solvent, adding a photoinitiator and stirring the mixture to obtain an oily prepolymer solution; adjusting the concentration of the oily prepolymer solution to between 200 and 500 cSt; (2) dissolving the polyvinyl alcohol modified polymer and the water-soluble drug in pure water, and stirring evenly to obtain an aqueous prepolymer solution; adjusting the concentration of the aqueous prepolymer solution to between 1 and 30 cSt; (3) The microspheres are obtained by outputting the microfluidic technology, with the oily prepolymer as the oil phase and the aqueous prepolymer as the water phase. The flow rate of the oil phase is between 30-100 μL / min, and the flow rate of the water phase is between 1-6 μL / min. (4) The microspheres obtained by microfluidics flow into an aqueous solution containing a surfactant and glutaraldehyde, and the collected solution is continuously stirred at 100-200 rpm for 2-4 hours under ultraviolet light with a wavelength of 200-400 nm; (5) After filtering out the microspheres, spraying the drug composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; (6) After spraying, store the microspheres in physiological saline.
[0017] Further, the concentration of the water-soluble drug in the aqueous phase is between 20-80 mg / ml; Furthermore, the mass ratio of the macromolecule containing the phosphazene structure to the amide monomer is between 1.5-2.5:1; Furthermore, the concentration of the oily drug is between 40-80 mg / ml; the oily drug can also be dispersed in the oily solvent in the form of nanoparticles.
[0018] Furthermore, in the aqueous solution containing a surfactant and glutaraldehyde, the mass concentration of the surfactant is between 1.5-4%; and the mass concentration of glutaraldehyde is between 2-4%.
[0019] Furthermore, the preparation process of the microspheres is as follows: the photoinitiator is an oil-soluble photoinitiator, including but not limited to one of DETX, TPO, and Darocur1173.
[0020] Furthermore, the wavelength of the selected ultraviolet light should be within the wavelength range corresponding to the photoinitiator, such as within the range of 200-370 nm.
[0021] Furthermore, the preparation process of the microspheres is as follows: the surfactant is one of Span 80, Tween 80, Tween 20, and biomass surfactant lecithin.
[0022] Furthermore, the oily drugs include but are not limited to one of paclitaxel and oily doxorubicin; the water-soluble drugs include but are not limited to one of rapamycin, fluorouracil, oxaliplatin, carmustine, epiroxacin hydrochloride, and doxorubicin hydrochloride.
[0023] Furthermore, the drug composite solution sprayed on the surface of the microspheres by a nano-scale atomization spray device includes a solvent, a drug and a drug excipient; the solvent is a DMSO / water solution with a mass fraction of 6-14%, and the drug includes but is not limited to doxorubicin hydrochloride, rapamycin, and epirubicin hydrochloride; the drug excipients include mannitol, sorbitol, etc.; the mass concentration of the drug is between 1-3%; and the mass concentration of the excipient is between 0.01-0.05%.
[0024] Furthermore, the surface spraying drug compound solution may also include other drugs with weaker polarity dissolved in non-polar or weakly polar solvents.
[0025] Furthermore, the particle size can be between 400-1000 μm, the shell thickness can be between 100-450 μm, and the thickness of the outermost surface drug coating layer can be between 15-30 nm.
[0026] Furthermore, the shell thickness and the microsphere particle size are reduced in substantially equal proportions.
[0027] Furthermore, the surface-loaded drug is transferred to the blood vessels within 2-4 hours.
[0028] Furthermore, the drug loaded in the microspheres can be sustained-released within 40-80 days.
[0029] Furthermore, the microspheres swell in equilibrium in physiological saline, and the ratio of their volume to the volume when flowing out of the microfluidics is between 1.05-1.5.
[0030] Furthermore, the microspheres can withstand a limit compression deformation between 60% and 90%. If the limit is exceeded, the microspheres cannot recover their shape. Within the compression limit, the microspheres can recover their shape. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 This is the appearance of the drug-loaded microspheres prepared in Example 1; Figure 2 This is the structure diagram of the drug-loaded microspheres prepared in Example 1 after freeze-drying; Figure 3 The release curve of the aqueous drug doxorubicin hydrochloride in normal saline of the drug-loaded microspheres prepared in Example 1; Figure 4 This is the release curve of the medium oil drug paclitaxel loaded with drug microspheres prepared in Example 1 in normal saline. DETAILED DESCRIPTION
[0034] The embodiments of the present application will be described in detail below in conjunction with examples, but those skilled in the art will understand that the following examples are only used to illustrate the present application and should not be construed as limiting the scope of the present application. Example 1
[0035] A gel embolic microsphere capable of loading multiple drugs and sustained release comprises an oily drug-loaded core, a hydrophilic drug-loaded shell and a surface drug-loaded layer; wherein the oily drug-loaded core comprises a macromolecule containing a phosphazene structure, an amide-based polymer and an oily drug; the hydrophilic drug-loaded shell is a polyvinyl alcohol-modified polymer and a water-soluble drug solution, and the outer layer of the hydrophilic drug-loaded shell realizes the introduction of a surface drug covering layer by accessing surfactant groups.
[0036] Furthermore, the oily drug-carrying core includes poly(bis(2,2,2-trifluoroethoxy)phosphazene), poly(3-acrylamide-phenol) and the oily drug paclitaxel; the hydrophilic shell is composed of anion-modified polyvinyl alcohol and doxorubicin hydrochloride solution, wherein the anion-modified polyvinyl alcohol is obtained by copolymerization of vinyl alcohol and sodium 2-acrylamide-2-methylpropyl sulfonate (SAMPS) followed by alcoholysis, with a molecular weight of 4360, an alcoholysis degree of 82%, and a sulfonate concentration of 0.62 mol / mol PVA after modification.
[0037] Furthermore, the preparation process of the microspheres is: (1) Dissolving poly(bis(2,2,2-trifluoroethoxy)phosphazene), (3-acrylamide-phenol) and paclitaxel in chloroform, adding TPO and stirring evenly to obtain an oily prepolymer solution; the concentration of the oily prepolymer solution is adjusted to 300 cSt; wherein the mass ratio of poly(bis(2,2,2-trifluoroethoxy)phosphazene) to (3-acrylamide-phenol) is 2.2, and the concentration of paclitaxel is 60 mg / ml; (2) Dissolve the polyvinyl alcohol modified polymer and doxorubicin hydrochloride in water, stir evenly to obtain an aqueous phase prepolymer solution, and adjust the concentration to 12 cSt; the concentration of doxorubicin hydrochloride is 35 mg / ml; (3) The microspheres were obtained by outputting the microfluidic technology, with the oily prepolymer as the oil phase and the aqueous prepolymer as the water phase. The flow rate of the oil phase was between 85 μL / min and the flow rate of the water phase was 3.5 μL / min. (4) The microspheres obtained by microfluidics flow into an aqueous solution containing Tween 80 and glutaraldehyde, and the collected solution is continuously stirred at 150 rpm for 3 hours under ultraviolet light with a wavelength of 350 nm; wherein the mass concentration of Tween 80 is 3.2%, and the mass concentration of glutaraldehyde is 3.5%; (5) After filtering out the microspheres, spraying the drug composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; wherein the drug composite aqueous solution is a rapamycin aqueous solution with a mass concentration of 2.5%, which contains mannitol with a mass concentration of 0.02%;
[0038] (6) After spraying, store the microspheres in physiological saline.
[0039] like Figure 1 As shown, the particle size of the prepared microspheres is between 300-550 μm, and the shell thickness is between 200-400 μm; like Figure 2 As shown, the core and shell structures of the prepared microspheres have obvious differences; The thickness of the outermost surface drug coating layer is 22 nm.
[0040] The surface loaded drug rapamycin is transferred to the embolized blood vessel within 4 hours.
[0041] like Figure 3 As shown, the doxorubicin hydrochloride loaded in the microspheres can be continuously released within 34 days.
[0042] like Figure 4 As shown, the drug paclitaxel loaded in the microspheres can be continuously released within 46 days.
[0043] The microspheres swelled in equilibrium in physiological saline, with the ratio of volume to volume when flowing out of the microfluidics being 1.34, mainly due to the swelling of the outer hydrophilic shell layer.
[0044] The microspheres can withstand an ultimate compression deformation of 86%.
[0045] Example 2 A gel embolic microsphere capable of loading multiple drugs and sustained release comprises an oily drug-loaded core, a hydrophilic drug-loaded shell and a surface drug-loaded layer; wherein the oily drug-loaded core comprises a macromolecule containing a phosphazene structure, an amide-based polymer and an oily drug; the hydrophilic drug-loaded shell is a polyvinyl alcohol-modified polymer and a water-soluble drug solution, and the outer layer of the hydrophilic drug-loaded shell realizes the introduction of a surface drug covering layer by accessing surfactant groups.
[0046] Furthermore, the oily drug carrier core includes poly(bis(phenoxy)phosphazene), poly(N-p-hydroxyphenylacrylamide) and oily drug oily doxorubicin; the hydrophilic drug carrier shell is composed of anion-modified polyvinyl alcohol and epichlorohydrin hydrochloride solution, wherein the anion-modified polyvinyl alcohol is modified with polyvinyl alcohol, triethylamine and epichlorohydrin as raw materials, has a molecular weight of 6200, a degree of alcoholysis of 84%, and the concentration of the quaternary ammonium salt after modification is 0.65 mol / mol PVA.
[0047] Furthermore, the preparation process of the microspheres is: (1) dissolving poly(bis(phenoxy)phosphazene), N-p-hydroxyphenylacrylamide, and oily doxorubicin in ethylene glycol ether, adding DETX photoinitiator and stirring evenly to obtain an oily prepolymer solution; the concentration of the oily prepolymer solution is adjusted to 350 cSt; wherein the mass ratio of poly(bis(phenoxy)phosphazene) to N-p-hydroxyphenylacrylamide is 1.8, and the concentration of the oily doxorubicin is 50 mg / ml; (2) Dissolve the polyvinyl alcohol modified polymer and epifloxacin hydrochloride in water and stir to obtain an aqueous phase; adjust the concentration of the aqueous phase to 18 cSt; and the concentration of epifloxacin hydrochloride to 40 mg / ml; (3) The microspheres were obtained by microfluidic technology, with the flow rate of the oil phase being between 70 μL / min and the flow rate of the water phase being 6.5 μL / min; (4) The microspheres obtained by microfluidics flow into an aqueous solution containing Tween 20 and glutaraldehyde, and the collected solution is continuously stirred at 180 rpm for 3 hours under ultraviolet light irradiation with a wavelength of 320 nm; wherein the mass concentration of Tween 80 is 2.8%, and the mass concentration of glutaraldehyde is 3.2%; (5) After filtering out the microspheres, spraying the drug composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; wherein the drug composite aqueous solution is a rapamycin aqueous solution with a mass concentration of 3%, which contains mannitol with a mass concentration of 0.01%; (6) After spraying, store the microspheres in physiological saline.
[0048] The particle size of the prepared microspheres is between 400-550 μm, the shell thickness is between 120-180 μm, and the thickness of the outermost surface drug coating layer is 25 nm.
[0049] The surface-loaded drug rapamycin is transferred to the blood vessels within 4 hours.
[0050] The microspheres are loaded with epirofloxacin hydrochloride, a drug, and can be sustained-released within 32 days.
[0051] The oily doxorubicin loaded in the microspheres can be continuously released within 48 days.
[0052] The microspheres swelled in equilibrium in physiological saline, with the ratio of volume to volume when flowing out in microfluidics being 1.37, mainly due to the swelling of the outer hydrophilic shell layer.
[0053] The microspheres can withstand an ultimate compression deformation of 82%.
[0054] Example 3 A gel embolic microsphere capable of loading multiple drugs and sustained release comprises an oily drug-loaded core, a hydrophilic drug-loaded shell and a surface drug-loaded layer; wherein the oily drug-loaded core comprises a macromolecule containing a phosphazene structure, an amide-based polymer and an oily drug; the hydrophilic drug-loaded shell is a polyvinyl alcohol-modified polymer and a water-soluble drug solution, and the outer layer of the hydrophilic drug-loaded shell realizes the introduction of a surface drug covering layer by accessing surfactant groups.
[0055] Furthermore, the oily drug carrier core includes poly(bis(4-carboxyphenoxy)phosphazene), poly(3-acrylamidophenylboronic acid) and the oily drug paclitaxel; the hydrophilic drug carrier shell is composed of anion-modified polyvinyl alcohol and fluorouracil aqueous solution, wherein the anion-modified polyvinyl alcohol is obtained by copolymerization of acrylic acid and vinyl acetate followed by alcoholysis, with a molecular weight of 7280, an alcoholysis degree of 84%, and a carboxylate concentration of 0.58 mol / mol PVA after modification.
[0056] Furthermore, the preparation process of the microspheres is: (1) Dissolving poly(bis(4-carboxyphenoxy)phosphazene), 3-acrylamidophenylboronic acid, and doxorubicin liposomes in ethyl acetate, adding Darocur 1173, and stirring evenly to obtain an oily prepolymer solution; the concentration of the oily prepolymer solution is adjusted to 420 cSt; wherein the mass ratio of poly(bis(4-carboxyphenoxy)phosphazene) to 3-acrylamidophenylboronic acid is 1.8, and the concentration of doxorubicin liposomes is 70 mg / ml; (2) Dissolve the polyvinyl alcohol modified polymer and carmustine in water, stir evenly to obtain an aqueous phase prepolymer solution, and adjust the concentration to 8 cSt; the concentration of carmustine is 32 mg / ml; (3) The microspheres were obtained by outputting the microfluidic technology, with the oily prepolymer as the oil phase and the aqueous prepolymer as the water phase. The flow rate of the oil phase was between 72 μL / min and the flow rate of the water phase was 4.5 μL / min. (4) The microspheres obtained by microfluidics flow into an aqueous solution containing Tween 20 and glutaraldehyde, and the collected solution is continuously stirred at 180 rpm for 3.5 hours under ultraviolet light with a wavelength of 320 nm; wherein the mass concentration of Tween 20 is 3.5%, and the mass concentration of glutaraldehyde is 3.0%; (5) After filtering out the microspheres, spraying the drug composite aqueous solution on the surface of the microspheres with a nano-scale atomization spray device; wherein the drug composite aqueous solution is a rapamycin aqueous solution with a mass concentration of 2.2%, which contains mannitol with a mass concentration of 0.04%;
[0057] (6) After spraying, store the microspheres in physiological saline.
[0058] The prepared particle size is between 500-650 μm, the shell thickness is between 200-350 μm, and the thickness of the outermost surface drug coating layer is 30 nm.
[0059] The surface loaded drug rapamycin is transferred to the embolized blood vessel within 3.5 hours.
[0060] The microspheres are loaded with doxorubicin hydrochloride, a drug, and can be sustained-released within 33 days.
[0061] The paclitaxel drug loaded in the microspheres can be continuously released within 51 days.
[0062] The microspheres swelled in equilibrium in physiological saline, and the ratio of their volume to the volume when flowing out of the microfluidics was 1.26.
[0063] The microspheres can withstand an ultimate compression deformation of 86%.
Claims
1. A gel embolic microsphere capable of loading multiple drugs and sustained release, comprising an oily drug-loaded core, a hydrophilic drug-loaded shell and a surface drug covering layer; wherein: The oily drug carrier core includes macromolecules containing phosphazene structure, amide polymers and oily drugs; the hydrophilic drug carrier shell includes polyvinyl alcohol modified polymers and water-soluble drug solution, and the outer layer of the hydrophilic drug carrier shell realizes the introduction of the surface drug covering layer by accessing the surfactant groups.
2. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The macromolecule containing the phosphazene structure includes one of poly(bis(2,2,2-trifluoroethoxy)phosphazene), poly(bis(phenoxy)phosphazene), and poly(bis(4-carboxyphenoxy)phosphazene), and the material structure is as follows: Poly(bis(2,2,2-trifluoroethoxy)phosphazene): ; Poly(bis(phenoxy)phosphazene): ; Poly(bis(4-carboxyphenoxy)phosphazene): .
3. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The amide polymer is a polymer obtained by polymerizing 3-acrylamide-phenol, N-p-hydroxyphenylacrylamide, and 3-acrylamidephenylboronic acid as monomers; the monomer structural formula is as follows: 3-Acrylamido-phenol: ; N-p-Hydroxyphenylacrylamide: ; 3-Acrylamidophenylboronic acid monomer: .
4. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The polyvinyl alcohol modified polymer of the hydrophilic drug-carrying shell is cation-modified polyvinyl alcohol or anion-modified polyvinyl alcohol; wherein the cation-modified polyvinyl alcohol is quaternary ammonium cationic polyvinyl alcohol, and the anion-modified polyvinyl alcohol is sulfonic acid polyvinyl alcohol or carboxyl polyvinyl alcohol, and the ion concentration is between 0.5-0.8 mol / mol polyvinyl alcohol.
5. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The preparation process of the microspheres is: (1) dissolving a macromolecule containing a phosphazene structure, an amide monomer, and an oily drug in an oily solvent, adding a photoinitiator and stirring the mixture to obtain an oily prepolymer solution; adjusting the concentration of the oily prepolymer solution to between 200 and 500 cSt; (2) dissolving the polyvinyl alcohol modified polymer and the water-soluble drug in pure water and stirring them evenly to obtain an aqueous prepolymer solution; The concentration of the aqueous prepolymer solution is adjusted to between 1-30 cSt; (3) The microspheres are obtained by outputting the microfluidic technology, with the oily prepolymer as the oil phase and the aqueous prepolymer as the water phase. The flow rate of the oil phase is between 30-100 μL / min, and the flow rate of the water phase is between 1-6 μL / min. (4) The microspheres obtained by microfluidics flow into an aqueous solution containing a surfactant and glutaraldehyde, and the collection solution is continuously stirred at 100-200 rpm for 2-4 hours under ultraviolet light with a wavelength of 200-400 nm; (5) After filtering out the microspheres, spray the drug compound solution on the surface of the microspheres using a nano-scale atomization spray device; (6) After spraying, the microspheres are stored in physiological saline; The concentration of the water-soluble drug in the aqueous phase is between 20-80 mg / ml; The mass ratio of the macromolecule containing the phosphazene structure to the amide monomer is between 1.5-2.5:1; The concentration of the oily drug is between 40-80 mg / ml; In the aqueous solution containing a surfactant and glutaraldehyde, the mass concentration of the surfactant is between 1.5-4%, and the mass concentration of glutaraldehyde is between 2-4%.
6. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 5, characterized in that: The photoinitiator is one of DETX, TPO and Darocur1173.
7. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 5, characterized in that: The surfactant is one of Span 80, Tween 80, Tween 20, and biomass surfactant lecithin.
8. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The oily drugs include paclitaxel and oily doxorubicin; the water-soluble drugs include rapamycin, fluorouracil, oxaliplatin, carmustine, epiroxacin hydrochloride and doxorubicin hydrochloride.
9. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claims 1 and 5, characterized in that: The drug compound solution sprayed on the surface of the microsphere by the nano-scale atomization spraying device comprises a solvent, a drug and a drug excipient.
10. The gel embolic microsphere capable of loading multiple drugs and sustained release as claimed in claim 1, characterized in that: The particle size of the prepared microspheres is between 400-1000 μm, the thickness of the hydrophilic drug-carrying shell is between 100-450 μm, and the thickness of the outermost surface drug coating layer is between 15-30 nm.
